ZEISS presents the new IOLMaster 700 for better predictability and optimized workflows in cataract surgery

The IOLMaster® 700 with SWEPT Source Biometry™ enables physicians to identify irregular geometries of their patients eyes at an early stage. In addition to optical biometry, it also offers OCT imaging across the entire length of the eye. Experts believe this insight will reduce surprises in cataract treatment and achieve more reliable refractive results. The device simplifies the workflow for the implantation of toric IOLs: similar to the standard-setting IOLMaster 500, it takes a reference image of the limbal blood vessels, which allows the cylinder axis to be displayed intraoperatively in the surgical microscope as a navigational aid for the surgeon

JENA/Germany, LONDON/UK, 13/09/2014.

ZEISS presents the first device with SWEPT Source Biometry at this year's Summer Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in London: The new IOLMaster 700 allows to identify irregular geometries of the eye or insufficient fixation already during the diagnosis. Apart from optical biometry, it also offers OCT imaging across the entire length of the eye. The IOL Master 700 enables cataract surgeons to view the complete longitudinal section of the eye, from the cornea to the retina. Irregular eye geometries, for example tilting of the lens axis, are therefore easier to identify. It is expected that this will facilitate a reduction in refractive surprises.

“Thanks to its new technology platform, the new IOLMaster 700 has the potential to significantly improve the refractive results of cataract operations. ZEISS is therefore bringing about another fundamental change in biometry," says Prof. Dr. Ekkehard Fabian from the Rosenheim Eye Clinic.

Imaging of the fovea in the macula lutea also allows physicians to check for correct fixation. Compared with previous procedures, in which the measurement result was derived from an A scan curve, the image-based measurement with the IOLMaster 700 brings both physician and patient added safety, as the expected refractive outcome can be more reliably predicted.

As with the IOLMaster 500, this new device also simplifies the workflows prior to cataract surgery. The Reference Image option eliminates the need for manual pre-operative and intraoperative marking of the astigmatism axis on the patient's eye before implantation of a toric IOL, as well as the necessity of manual data transfer. Both were previously necessary for alignment of the toric lenses.

"We would like to help our customers achieve the best outcomes possible for every patient. Our IOLMaster 700 therefore enables imaging of the biometric results," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. The crucial thing, according to Ludwin Monz, is that capturing OCT images along the entire length of the eye can save cataract surgeons and their patients from surprises later. "Up until now, even a flawless operation and a high-quality lens could have led to unsatisfactory results, if irregular eye geometries or inadequate fixation were overlooked. We believe that the IOLMaster 700 will now prevent most cases of this from happening. As a component of our ZEISS Cataract Suite markerless, the device also improves the workflow and increases efficiency during the implantation of toric lenses."

The IOLMaster 700 is fully compatible with previous versions and provides access to the database of the User Group of Laser Interference Biometry (ULIB). This database contains the lens constants of more than 270 IOL models and is based on more than 50,000 cataract operations. The unique "telecentric keratometry" allows particularly robust and reproducible measurement of the corneal surface.

The product will be available in Europe from autumn 2014, and in other countries from 2015.

ZEISS presents the new IOLMaster 700 with SWEPT Source Biometry for better predictability and optimized workflows in cataract surgery.

ZEISS presents the new IOLMaster 700 with SWEPT Source Biometry for better predictability and optimized workflows in cataract surgery.

Image Download (JPG File · 1.9 MB)

Press contact:
Jann Gerrit Ohlendorf, Group Communications, Carl Zeiss Meditec AG
Phone: +49 3641 220-331, Email: press .meditec @zeiss .com

For investors:
Sebastian Frericks, Investor Relations, Carl Zeiss Meditec AG
Phone: +49 3641 220-116, Email: investors .meditec @zeiss .com

About Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases – including implants and consumable materials. The company creates innovative visualisation solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In financial year 2012/2013 (ended 30 September) the Group's more than 2,500 employees generated revenue of almost € 906 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.